ITALY, March 12th 2016 – Corion Biotech is pleased to announce that it has been granted an international patent in Europe concerning the therapeutic treatment of preeclampsia using placental mesenchymal stem cells derived biological product.

Preeclampsia is a life-threatening pregnancy-related disease which affects 2-8% of all pregnancies worldwide. It is a serious disorder characterized by the new onset of hypertension, proteinuria and/or other signs of maternal vascular and organ damage which may lead to maternal and foetal morbidity and mortality.

Today preeclampsia is an unsolved medical need. No specific treatments are available, the only definitive cure is delivery of the foetus and the placenta, which often occurs prematurely leading to several complications and long term associated risks.